# US 2021/0341490 A1 · Methods for detecting and/or measuring anti-drug antibodies, in particular treatment-emergent anti-drug antibodies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0341490 A1
- Document ID: US20210341490A1
- Status: Published application
- Kind: A1
- Application number: 17/229,119
- Filed: 2021-04-13
- Published: 2021-11-04
- Earliest claimed: 2014-05-16
- Assignees: Ablynx N.V.
- Applicants: Ablynx N.V.
- Inventors: Veerle Snoeck; Marie-Ange Buyse; Judith Baumeister
- Web page: https://patentgrep.com/patent/US20210341490A1

## CPC

- G01N 33/6854: {Immunoglobulins}
- G01N 33/6857: {Antibody fragments}
- G01N 33/94: involving narcotics {or drugs or pharmaceuticals, neurotransmitters or associated receptors}
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Described herein are methods, assays and techniques for detecting and/or measuring anti-drug antibodies that bind to a protein, polypeptide or other compound or molecule that comprises at least one immunoglobulin variable domain with an exposed C-terminal region.

## Claims

### Claim 1

Method for detecting and/or measuring anti-drug antibodies against a protein, polypeptide or other compound or molecule that comprises at least one immunoglobulin variable domain with an exposed C-terminal region in a sample, said method comprising at least the steps of:
a) contacting said sample with a capturing agent that is immobilized on a support, wherein said capturing agent is or essentially consists of said protein, polypeptide or other compound or molecule, under conditions such that any anti-drug antibodies against said protein, polypeptide or other compound or molecule can bind to said capturing agent;
b) (optionally) removing any components or constituents present in said sample that do not bind to the capturing agent;
c) detecting or measuring any anti-drug antibodies that have bound to the capturing agent, by contacting the complex of the capturing agent and any captured anti-drug antibodies with a detection agent, under conditions such that said detection agent can bind to (the complex of the capturing agent and) any captured anti-drug antibodies,
wherein either:
x) said capturing agent is or essentially consists of: (i) said protein, polypeptide or other compound or molecule (immobilized on the solid support); and (ii) 1-5 amino acid residues that are linked to the exposed C-terminal end of the immunoglobulin variable domain with the exposed C-terminal region that is comprised within the protein, polypeptide or other compound or molecule;
or:
y) said detection agent is or essentially consists of: (i) said protein, polypeptide or other compound or molecule; (ii) a detectable tag or label bound to said protein, polypeptide or other compound or molecule (either directly or via a suitable linker) and (iii) 1-5 amino acid residues that are linked to the exposed C-terminal end of the immunoglobulin variable domain with the exposed C-terminal region that is comprised within the protein, polypeptide or other compound or molecule,
in which said sample is a sample of whole blood, serum, plasma, ocular fluid, bronchoalveolar fluid/BALF, cerebrospinal fluid or other biological fluid.

### Claim 2 (depends on 1)

Method according to claim 1, in which said capturing agent is or essentially consists of: (i) said protein, polypeptide or other compound or molecule (immobilized on the solid support); and (ii) 1-5 amino acid residues that are linked to the exposed C-terminal end of the immunoglobulin variable domain with the exposed C-terminal region that is comprised within the protein, polypeptide or other compound or molecule;

### Claim 3 (depends on 1)

Method according to claim 1, in which the capturing agent has the amino acid sequence VTVSS(X)n (SEQ ID NO: 2) at its C-terminal end, in which n is 1 to 10, preferably 1 to 5, such as 1, 2, 3, 4 or 5 (and preferably 1 or 2, such as 1); and in which each X is an (preferably naturally occurring) amino acid residue that is independently chosen (and preferably independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I)).

### Claim 4 (depends on 1)

Method according to claim 1, in which said detection agent is or essentially consists of: (i) said protein, polypeptide or other compound or molecule; (ii) a detectable tag or label bound to said protein, polypeptide or other compound or molecule (either directly or via a suitable linker) and (iii) 1-5 amino acid residues that are linked to the exposed C-terminal end of the immunoglobulin variable domain with the exposed C-terminal region that is comprised within the protein, polypeptide or other compound or molecule.

### Claim 5 (depends on 1)

Method according to claim 1, in which the detection agent has the amino acid sequence VTVSS(X)n (SEQ ID NO: 2) at its C-terminal end, in which n is 1 to 10, preferably 1 to 5, such as 1, 2, 3, 4 or 5 (and preferably 1 or 2, such as 1); and in which each X is an (preferably naturally occurring) amino acid residue that is independently chosen (and preferably independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I)).

### Claim 6

(canceled)

### Claim 7 (depends on 1)

Method according to claim 1, in which the sample has been obtained from a subject to which said protein, polypeptide or other compound or molecule has been administered and wherein the protein, polypeptide or other compound or molecule has been administered to a subject according to a regimen that is such that there is a risk or possibility that anti-drug antibodies against protein, polypeptide or other compound or molecule have been raised in the subject to which said protein, polypeptide or other compound or molecule has been administered.

### Claim 8 (depends on 1)

Method according to claim 1, in which the protein, polypeptide or other compound or molecule has a half-life of at least 1 day, preferably at least 3 days, more preferably at least 7 days, such as at least 10 days, in a human subject.

### Claim 9 (depends on 1)

Method according to claim 1, in which the at least one immunoglobulin variable domain with the exposed C-terminal region comprised within the protein, polypeptide or other compound or molecule is an VH domain or has been derived from a VH domain.

### Claim 10 (depends on 1)

Method according to claim 1, in which the at least one immunoglobulin variable domain with the exposed C-terminal region comprised within the protein, polypeptide or other compound or molecule is an immunoglobulin single variable domain.

### Claim 11 (depends on 1)

Method according to claim 1, in which the at least one immunoglobulin variable domain with the exposed C-terminal region comprised within the protein, polypeptide or other compound or molecule is a nanobody (such as, in particular, a VHH domain, a humanized VHH domain or a camelized VH domain such as a camelized human VH domain), a dAb or a (single) domain antibody.

### Claim 12 (depends on 1)

Method according to claim 1, in which the immunoglobulin variable domain with the exposed C-terminal region is present at the C-terminal end of said protein, polypeptide or other compound or molecule.

### Claim 13 (depends on 1)

Method according to claim 1, in which the C-terminal end of the immunoglobulin variable domain with the exposed C-terminal region has the sequence VTVSS (SEQ ID NO: 1).

### Claim 14 (depends on 1)

Method according to claim 1, in which the C-terminal end of the said protein, polypeptide or other compound or molecule has the sequence VTVSS (SEQ ID NO: 1).

### Claim 15 (depends on 1)

Method according to claim 1, in which the detectable tag or label comprised within the detection agent is a tag or label that can be detected using electrochemiluminescence techniques.
